BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sturgeon JP, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. Expert Rev Gastroenterol Hepatol. 2014;8:83-100. [PMID: 24236755 DOI: 10.1586/17474124.2014.858598] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hatton G, Shawcross DL. Is treating the gut microbiome the key to achieving better outcomes in cirrhosis? Expert Review of Gastroenterology & Hepatology 2018;13:1-2. [DOI: 10.1080/17474124.2019.1543587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
2 Lauridsen MM, Schaffalitzky de Muckadell OB, Vilstrup H. Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests. Metab Brain Dis. 2015;30:1187-1192. [PMID: 26016624 DOI: 10.1007/s11011-015-9688-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
3 Hadjihambi A, Jalan R. Hepatic encephalopathy: New treatments. Clin Liver Dis (Hoboken) 2015;5:109-11. [PMID: 31040962 DOI: 10.1002/cld.468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
5 Naderian M, Akbari H, Saeedi M, Sohrabpour AA. Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial. Middle East J Dig Dis 2017;9:12-9. [PMID: 28316761 DOI: 10.15171/mejdd.2016.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
6 Vidot H, Potter A, Cheng R, Allman-Farinelli M, Shackel N. Serum 25-hydroxyvitamin D deficiency and hepatic encephalopathy in chronic liver disease. World J Hepatol 2017; 9(10): 510-518 [PMID: 28443156 DOI: 10.4254/wjh.v9.i10.510] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
8 Meng LP, Chen YC, Li YH, Zhu JS, Ye JL. Viability assessment of magnetic resonance spectroscopy for the detection of minimal hepatic encephalopathy severity. Eur J Radiol 2015;84:2019-23. [PMID: 26170124 DOI: 10.1016/j.ejrad.2015.06.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev 2019;6:CD012334. [PMID: 31204790 DOI: 10.1002/14651858.CD012334.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2019;1:CD011451. [PMID: 30610762 DOI: 10.1002/14651858.CD011451.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kristiansen RG. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure. Metab Brain Dis 2016;31:1357-8. [PMID: 27651377 DOI: 10.1007/s11011-016-9908-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Mahmoud AM, Alqahtani S, Othman SI, Germoush MO, Hussein OE, Al-Basher G, Khim JS, Al-Qaraawi MA, Al-Harbi HM, Fadel A, Allam AA. Commiphora molmol Modulates Glutamate-Nitric Oxide-cGMP and Nrf2/ARE/HO-1 Pathways and Attenuates Oxidative Stress and Hematological Alterations in Hyperammonemic Rats. Oxid Med Cell Longev 2017;2017:7369671. [PMID: 28744340 DOI: 10.1155/2017/7369671] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
13 Afifi MAE, Hussein AM, Rizk M. Low Serum 25-Hydroxy Vitamin D (25-OHD) and Hepatic Encephalopathy in HCV-Related Liver Cirrhosis. Int J Hepatol 2021;2021:6669527. [PMID: 33628512 DOI: 10.1155/2021/6669527] [Reference Citation Analysis]
14 Spacek LA, Mudalel ML, Lewicki R, Tittel FK, Risby TH, Stoltzfus J, Munier JJ, Solga SF. Breath ammonia and ethanol increase in response to a high protein challenge. Biomarkers 2015;20:149-56. [PMID: 26043432 DOI: 10.3109/1354750X.2015.1040840] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
15 Weiner ID, Verlander JW. Ammonia Transporters and Their Role in Acid-Base Balance. Physiol Rev 2017;97:465-94. [PMID: 28151423 DOI: 10.1152/physrev.00011.2016] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
16 Zhang S, Zhao Y, Ohland C, Jobin C, Sang S. Microbiota facilitates the formation of the aminated metabolite of green tea polyphenol (-)-epigallocatechin-3-gallate which trap deleterious reactive endogenous metabolites. Free Radic Biol Med 2019;131:332-44. [PMID: 30578921 DOI: 10.1016/j.freeradbiomed.2018.12.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
17 Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016;64:1265-72. [PMID: 27474889 DOI: 10.1002/hep.28737] [Cited by in Crossref: 102] [Cited by in F6Publishing: 88] [Article Influence: 17.0] [Reference Citation Analysis]
18 Jepsen P, Watson H, Andersen PK, Vilstrup H. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol. 2015;63:1133-1138. [PMID: 26206073 DOI: 10.1016/j.jhep.2015.07.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
19 Jia G, Wang R, Yue Y, Dai H. Activation of Protein Kinase Cδ Contributes to the Induction of Src/EGF Receptor/ERK Signaling in Ammonia-treated Astrocytes. J Mol Neurosci 2020;70:1110-9. [PMID: 32125625 DOI: 10.1007/s12031-020-01517-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Ferro JM, Viana P, Santos P. Management of Neurologic Manifestations in Patients with Liver Disease. Curr Treat Options Neurol 2016;18:37. [PMID: 27314429 DOI: 10.1007/s11940-016-0419-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
21 Dynnik VV, Kononov AV, Sergeev AI, Teplov IY, Tankanag AV, Zinchenko VP. To Break or to Brake Neuronal Network Accelerated by Ammonium Ions? PLoS One 2015;10:e0134145. [PMID: 26217943 DOI: 10.1371/journal.pone.0134145] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
22 Shafey GM, Rashed ER, Zaki HF, Attia AS, El-Ghazaly MA. Molecular mechanisms involved in the effects of morin in experimental hepatic encephalopathy. Biofactors 2022. [PMID: 35332953 DOI: 10.1002/biof.1838] [Reference Citation Analysis]
23 Martí-carvajal AJ, Gluud C, Arevalo-rodriguez I; Cochrane Hepato-Biliary Group. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd011451] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Huang FZ, Hou X, Zhou TQ, Chen S. Hepatic encephalopathy coexists with acquired chronic hepatocerebral degeneration. Neurosciences (Riyadh) 2015;20:277-9. [PMID: 26166598 DOI: 10.17712/nsj.2015.3.20140759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
25 Tamaoki S, Suzuki H, Okada M, Fukui N, Isobe M, Saito T. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin. European Journal of Pharmacology 2016;779:168-76. [DOI: 10.1016/j.ejphar.2016.03.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
26 Sun X, Lv Y, Huang L, Gao H, Ren C, Li J, Bie M, Li W, Koike K, So KF, Xiao J. Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis and Lycium barbarum polysaccharides protection. J Ethnopharmacol 2020;248:112357. [PMID: 31693919 DOI: 10.1016/j.jep.2019.112357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Li M, Zhang Z, Chen Q, Zhou X, Shui D, Huang J. Comparative Effectiveness and Safety of Polyethylene Glycol Electrolyte Solution Versus Lactulose for Treatment of Hepatic Encephalopathy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2022;56:41-8. [PMID: 34739404 DOI: 10.1097/MCG.0000000000001621] [Reference Citation Analysis]
28 DuPont HL. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. Mayo Clin Proc. 2015;90:1116-1124. [PMID: 26162610 DOI: 10.1016/j.mayocp.2015.04.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]